Discontinuation report MINT-RIVASTIGMINE
| Report ID | 13559 |
| Drug Identification Number | 02407019 |
| Brand name | MINT-RIVASTIGMINE |
| Common or Proper name | Rivastigmine |
| Company Name | MINT PHARMACEUTICALS INC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | RIVASTIGMINE |
| Strength(s) | 6MG |
| Dosage form(s) | CAPSULE |
| Route of administration | ORAL |
| Packaging size | Blister pack of 56 Capsules. |
| ATC code | N06DA |
| ATC description | ANTI-DEMENTIA DRUGS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | |
| Actual discontinuation date | 2017-06-30 |
| Remaining supply date | 2017-06-30 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 6575 DAVAND DRIVE MISSISSAUGA, ONTARIO CANADA L5T 2M3 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v3 | 2017-07-01 | English | Compare |
| v2 | 2017-06-21 | French | Compare |
| v1 | 2017-06-21 | English | Compare |
Showing 1 to 3 of 3